166 related articles for article (PubMed ID: 19214297)
1. Efficacy of alternate day versus daily dosing of rosuvastatin.
Dulay D; LaHaye SA; Lahey KA; Day AG
Can J Cardiol; 2009 Feb; 25(2):e28-31. PubMed ID: 19214297
[TBL] [Abstract][Full Text] [Related]
2. Impact of 10 mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers.
Li JJ; Yang P; Liu J; Jia YJ; Li ZC; Guo YL; Wu NQ; Tang YD; Jiang LX
Clin Chim Acta; 2012 Jan; 413(1-2):139-42. PubMed ID: 21983163
[TBL] [Abstract][Full Text] [Related]
3. Alternate day dosing of rosuvastatin: potential usefulness in statin-intolerant patients.
Joy T; Hegele RA
Can J Cardiol; 2009 Aug; 25(8):453. PubMed ID: 19678415
[No Abstract] [Full Text] [Related]
4. Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy.
Mackie BD; Satija S; Nell C; Miller J; Sperling LS
Am J Cardiol; 2007 Jan; 99(2):291. PubMed ID: 17223437
[TBL] [Abstract][Full Text] [Related]
5. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study.
Meek C; Wierzbicki AS; Jewkes C; Twomey PJ; Crook MA; Jones A; Viljoen A
Curr Med Res Opin; 2012 Mar; 28(3):371-8. PubMed ID: 22256801
[TBL] [Abstract][Full Text] [Related]
6. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study.
Leiter LA; Rosenson RS; Stein E; Reckless JP; Schulte KL; Schleman M; Miller P; Palmer M; Sosef F;
Atherosclerosis; 2007 Oct; 194(2):e154-64. PubMed ID: 17229426
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
Costa-Scharplatz M; Ramanathan K; Frial T; Beamer B; Gandhi S
Clin Ther; 2008 Jul; 30(7):1345-57. PubMed ID: 18691996
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia.
Stein EA; Amerena J; Ballantyne CM; Brice E; Farnier M; Guthrie RM; Harats D; Ma PT; Le Maulf F; Melezínková H; Gold A; Sager P
Am J Cardiol; 2007 Nov; 100(9):1387-96. PubMed ID: 17950795
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic interaction between ezetimibe and rosuvastatin.
Kosoglou T; Statkevich P; Yang B; Suresh R; Zhu Y; Boutros T; Maxwell SE; Tiessen R; Cutler DL
Curr Med Res Opin; 2004 Aug; 20(8):1185-95. PubMed ID: 15324521
[TBL] [Abstract][Full Text] [Related]
11. Superior benefit of aggressive lipid-lowering therapy for high- risk patients using statins: the SUBARU study--more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy.
Kurabayashi M; Yamazaki T;
J Atheroscler Thromb; 2008 Dec; 15(6):314-23. PubMed ID: 19060425
[TBL] [Abstract][Full Text] [Related]
12. Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia.
Saito Y; Goto Y; Dane A; Strutt K; Raza A
J Atheroscler Thromb; 2003; 10(6):329-36. PubMed ID: 15037821
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins.
Gadarla M; Kearns AK; Thompson PD
Am J Cardiol; 2008 Jun; 101(12):1747-8. PubMed ID: 18549851
[TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia.
Wongwiwatthananukit S; Sansanayudh N; Dhummauppakorn R; Kitiyadisai C
Ann Pharmacother; 2006 Nov; 40(11):1917-23. PubMed ID: 17003082
[TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin--a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients.
Schuster H
Cardiology; 2003; 99(3):126-39. PubMed ID: 12824720
[TBL] [Abstract][Full Text] [Related]
17. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A
Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760
[TBL] [Abstract][Full Text] [Related]
18. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Jones PH; Davidson MH; Stein EA; Bays HE; McKenney JM; Miller E; Cain VA; Blasetto JW;
Am J Cardiol; 2003 Jul; 92(2):152-60. PubMed ID: 12860216
[TBL] [Abstract][Full Text] [Related]
20. Impact of enhanced compliance initiatives on the efficacy of rosuvastatin in reducing low density lipoprotein cholesterol levels in patients with primary hypercholesterolaemia.
Riesen WF; Noll G; Dariolo R;
Swiss Med Wkly; 2008 Jul; 138(29-30):420-6. PubMed ID: 18654867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]